🇺🇸 FDA
Pipeline program

GS1191-0445 injection

GS1191-0445-GTHA-CN02

Phase 3 small_molecule active

Quick answer

GS1191-0445 injection for Hemophilia A is a Phase 3 program (small_molecule) at Gritgen Therapeutics Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Gritgen Therapeutics Co.,
Indication
Hemophilia A
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials